1 / 21

Update on Global TB Research

T reatment A ction G roup. Update on Global TB Research. By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis Centers for Disease Control and Prevention (CDC) March 20-21, 2007 Atlanta, Georgia. T reatment A ction G roup. Who is TAG?.

ailsa
Download Presentation

Update on Global TB Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment Action Group Update on Global TB Research By Claire Wingfield Treatment Action Group Advisory Council for the Elimination of Tuberculosis Centers for Disease Control and Prevention (CDC) March 20-21, 2007 Atlanta, Georgia

  2. Treatment Action Group Who is TAG? • Treatment Action Group (TAG) was founded in January, 1992, and is the first and only AIDS organization dedicated solely to advocating for larger and more efficient research efforts, both public and private, towards finding a cure for AIDS. • The TB/HIV Project works to combat TB/HIV co-infection through a combination of community-based advocacy, education and mobilization efforts involving AIDS advocates in developed and developing countries. The TB/HIV Project is supported by a grant from the Bill & Melinda Gates Foundation.

  3. Treatment Action Group TB Research • The 1940’s and 50’s were the heyday of TB drug discovery. • Between the 1940’s and 1980 there was dramatic decline in global TB disease, and as a result there was a stall in TB R&D. • But TB made a dramatic comeback with the dawn of the HIV pandemic.

  4. Treatment Action Group

  5. Treatment Action Group Methodology • Objective was to highlight gaps in spending as well as in areas of scientific study in TB R&D. • Funding data were collected largely from original-source donors. • Data were collected from public and private sector sources and were supplemented by interviews. • Most of the data is based on self-reporting by recipients and representatives of funding sources.

  6. Treatment Action Group Who Are the Funders? TOP 10 Donors to TB Research(2005) • NIAID / NIH • Gates Foundation • Medical Research Council (UK) • Other Institutes & Centers / NIH • Centers for Disease Control • Company X • Wellcome Trust • NHLBI / NIH • European Commission 6th Framework • Otsuka Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006

  7. Treatment Action Group Overall TB R&D Investment (2005 = $392.7M) Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006

  8. Treatment Action Group Investment in TB Research Actual vs. Need (2005) ? ? ? Feuer C. Tuberculosis Research & Development: A Critical Analysis. Treatment Action Group (TAG); 2006

  9. 2005 Spending Treatment Action Group

  10. 2005 Spending Treatment Action Group

  11. 2005 Spending Treatment Action Group

  12. 2005 Spending Treatment Action Group

  13. 2005 Spending Treatment Action Group

  14. Treatment Action Group

  15. Treatment Action Group

  16. Treatment Action Group

  17. Treatment Action Group

  18. 2005 Spending Treatment Action Group

  19. Why are the Global Plan Numbers Insufficient? Treatment Action Group How Much TB R&D Funding is Really Needed (Dollars in Millions) FY05 GP 2006 base 5-fold GP2 TAG 10 yr Actual estimate increase 2015 rec By new tool category TB diagnostics 16 59 80 516 900 TB drugs 120 418 600 4800 6000 TB vaccines 70 291 350 3641 3600 New tools sub. 206 768 1030 8957 10500 Basic research 94 0 470 0 4800 Applied/Infrastructure 44 0 220 0 2200 Operational research 50 0 250 0 2500 Subtotal 188 0 940 0 9500 Total TB R&D 394 768 1970 8957 20000

  20. Treatment Action Group Action Points • A comprehensive global TB R&D agenda is urgently needed. • TB R&D needs better global/national coordination. • Industry needs to be more transparent about TB R&D investments. • Reporting consistency is needed to better track and annually update TB R&D. Need greater involvement from all funders in TB R&D. • Emerging countries such as Brazil, China, India, Russia, South Africa and Thailand should play a bigger role. • A five-fold (400%) increase in annual TB R&D expenditures is the minimum necessary to achieve the goals set out in The Global Plan II.

  21. THANKS • Javid Syed, TAG • Mark Harrington, TAG • Eric Goemaere, MSF

More Related